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To be included in the review, the studies had to have a sample size of more than 30, have been carried out after 1980, and have a study population aged between 35 and 65 years. Smoking cessation compliance rates and effectiveness estimates were derived from randomised controlled trials.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Approximately 17 studies were included in the review.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
The base-case values are reported here along with the range used in the sensitivity analysis (in brackets).
The smoking quit rate was 11.35% (6.7 -16) with therapy and 5.75% (2.5 -9) without therapy.
The past compliance prevalence was 25% (10 -35) and the future compliance prevalence was 50% (40 -60).
The long-term drop out rate with maintenance therapy was 9.4% (4.9 -13.9).
Methods used to derive estimates of effectiveness
The estimates of positive and negative predictive values were derived from the authors' assumptions.
Estimates of effectiveness and key assumptions
The positive predictive value of the test was 97% (94 -100) and the negative predictive value was 97% (94 -100).
Measure of benefits used in the economic analysis
The measure of benefit was the QALY. The range of utility measures for mild and severe periodontitis was estimated from a literature review and from clinical opinion. The numbers of severe cases of periodontitis were also given. The QALYs were discounted at a rate of 3%.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
No indirect costs were reported.
Currency

US dollars ($).
Sensitivity analysis
A one-way sensitivity analysis was carried out on each parameter. The worst-and best-case scenarios were also analysed. The impact these had on the incremental costs, incremental QALYs, incremental cases of severe periodontitis and the incremental cost-effectiveness ratio (ICER), were examined.
Estimated benefits used in the economic analysis
The QALYs increased by 4.5 (from 18,745.8 to 18,750.3) for the whole cohort.
Cost results
Using a genetic test produced additional costs of $147,114 per 1,000 patients over the 30 years. These costs were discounted at a rate of 3%.
Synthesis of costs and benefits
In the base case, an ICER of $32,633 was obtained for testing compared with no testing.
For the worst-case set of parameters that favoured no testing, no testing dominated testing. In other words, the costs were less and the benefits higher for no testing. For the best-case set of parameters that favoured testing, testing dominated no testing.
The one-way sensitivity analyses showed that there were three variables that exhibited a significant impact on the results. These were patient compliance, the effectiveness of non-surgical therapy and the cost of the test.
When the treatment compliance was increased from 10 to 35%, the ICER increased from $12,651 to $231,365 per QALY.
When the effectiveness of the treatment risk ratio was varied from 0.7 to 0.3, the ICER varied from $61,510 to $18,786 per QALY.
When the cost of the test was varied from $100 to $300, the ICER varied from $10,451 to $54,816 per QALY.
